The most common acquired resistance mutation in the EGFR is T790M at exon 20.9, 10 The EGFR-T790M mutation and cMET amplification account for 50–60% and 5–20%, respectively, of the observed EGFR-TKI resistance in NSCLC patients.9, 10 The protein expression and phosphorylation of EGFR-T790M and cMET have been associated with both intrinsic and acquired resistance to TKI-targeting therapy in these patients. Here, EGFR is linked to non-small cell lung carcinoma.